Monte Rosa Therapeutics Initiates Phase 1 Study of NEK7-Directed Molecular Glue Degrader MRT-8102 for Inflammatory Diseases
Reuters
Aug 07, 2025
<a href="https://laohu8.com/S/GLUE">Monte Rosa Therapeutics</a> Initiates Phase 1 Study of NEK7-Directed Molecular Glue Degrader MRT-8102 for Inflammatory Diseases
Monte Rosa Therapeutics Inc., a clinical-stage biotechnology company, has announced the commencement of a Phase 1 study for its NEK7-directed molecular glue degrader, MRT-8102. This study aims to explore a novel therapeutic approach for treating inflammatory diseases driven by the NLRP3 inflammasome. Initial results from this study are anticipated in the first half of 2026. Additionally, Monte Rosa is advancing its VAV1-directed MGD, MRT-6160, towards the initiation of multiple Phase 2 studies in immune-mediated diseases, in collaboration with Novartis. The company also continues its Phase 1/2 study of GSPT1-directed MGD MRT-2359 in heavily pretreated, castration-resistant prostate cancer patients, with further results expected in the second half of 2025. Monte Rosa maintains a strong financial position to support operations into 2028, through multiple anticipated proof-of-concept clinical readouts.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Monte Rosa Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9507677-en) on August 07, 2025, and is solely responsible for the information contained therein.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.